GenVec, Inc. (Nasdaq:GNVC), a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines, announced that it has extended its Research Collaboration and License Agreement with Novartis. Under the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program.

"GenVec has worked closely with Novartis for the past two years to move this program forward and we remain committed to being a value added partner," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research. "This extension will allow GenVec to continue supporting this important effort."

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

*************************************************

First Marblehead Corporation (NYSE:FMD) plans to release its financial and operating results for the three-month period ended December 31, 2011 after the market closes on Tuesday, January 31, 2012. The Company will host a conference call at 5:00 p.m. Eastern time on Tuesday, January 31, 2012 to discuss its results. First Marblehead's Chairman and CEO Daniel Meyers and Chief Financial Officer Ken Klipper will host the call.

The First Marblehead Corporation, together with its subsidiaries, provides outsourcing services for designing and implementing private education loan programs to national and regional financial institutions, and educational institutions in the United States.

*************************************************

Iamgold Corporation (NYSE:IAG) will release its 2011 fourth quarter and full year financial results after market hours on Thursday February 23, 2012. A conference call will be held on Friday, February 24th at 9:00 a.m. (Eastern Standard Time) for a discussion with management regarding the Company's operating performance and financial results for the fourth quarter and full year 2011. A webcast of the conference call will be available through the Company's website - www.iamgold.com.

IAMGOLD Corporation, together with its subsidiaries, engages in the exploration, development, and production of mineral resource properties worldwide.

*************************************************

MoSys, Inc. (NASDAQ:MOSY), a provider of serial chip-to-chip communications solutions that deliver unparalleled bandwidth performance for next generation networking systems and advanced system-on-chip (SoC) designs, announced it will release its fourth quarter and full year 2011 financial results on Tuesday, February 7, 2012 after the market close. Following the press release, Len Perham, MoSys' President and Chief Executive Officer, and Jim Sullivan, Chief Financial Officer, will host a live audio webcast and conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

MoSys, Inc., together with its subsidiaries, designs, develops, markets, and licenses embedded memory intellectual property (IP) for systems on chips (SOCs) designs.

********************************************************************

********************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. BestOTC.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://bestotc.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold BestOTC.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.